Mochida Pharmaceutical Co., Ltd.
Notification Regarding Share Buyback
Engaged in share buyback. Targets 60,600 ordinary shares, total amount 192,845,500 yen, period 2026/6/1–2026/6/30, method is market purchase (Tokyo Stock Exchange).
Key Figures
- 60,600 shares: Total number of acquired shares
- 192,845,500 yen: Total acquisition value
- June 1, 2026 – June 30, 2026: Acquisition period
- Cumulative 95,900 shares: Cumulative total acquired around the above period
- Cumulative 317,160,500 yen: Cumulative total acquisition value around the above period
AI要約
Key points of the acquisition
Today, we disclosed the status of our share buyback. The target shares are ordinary shares, total number 60,600 shares, total acquisition value 192,845,500 yen. Acquisition period is from June 1, 2026 to June 30, 2026 on an execution basis, with the transaction method being market purchases. The maximum acquisition framework and period were disclosed based on the board of directors' meeting resolution held on March 30, 2026; cumulatively, as of June 30, 2026, total acquired shares are 95,900 shares, and total amount is 317,160,500 yen.
Market impact and future outlook
The share buyback is conducted as part of shareholder remittance measures, potentially aiming to counter dilution and support the share price. This acquisition is conducted via market purchases, and the cumulative status will continue to be disclosed. Future acquisition progress and any additional board resolutions are points to watch.
Molnex Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
